Methods for detecting and treating endometriosis

Patent metadata

Field	Value
Publication number	US-2025035647-A1
Application number	US-202418914567-A
Country	US
Kind code	A1
Filing date	Oct 14, 2024
Priority date	Mar 6, 2018
Publication date	Jan 30, 2025
Grant date	—

First claim

What is claimed is:

1 . A method of treating a chronic subclinical inflammation of a uterine lining in a subject comprising:
a) obtaining an identification of the subject as in need of treatment of chronic subclinical inflammation, wherein the subject has been identified so by: maintaining a stromal fibroblast cell (SFC), obtained from a menstrual discharge sample from the subject, under conditions permitting decidualization, quantifying a rate or extent of decidualization of the stromal fibroblast cell, and comparing the rate of decidualization to a control value of decidualization indicative of a subject without endometriosis, wherein a rate or extent of decidualization of the stromal fibroblast cell which is less than that of the control value of decidualization indicates that the subject has chronic subclinical inflammation; and b) treating the subject so-identified as having chronic subclinical inflammation by administering an amount of a small molecule or biologic anti-inflammatory agent effective to treat chronic subclinical inflammation of the uterine lining.

2 . The method of claim 1 , wherein the menstrual discharge sample comprises menstrual blood.

3 . The method of claim 1 , wherein the menstrual discharge sample has been obtained via a menstrual cup or polyether polyurethane menstrual sponge.

4 . The method of claim 1 , wherein the stromal fibroblast cell is contacted with 8-Br-CAMP and one or more hormones to effect decidualization.

5 . The method of claim 4 , wherein the one or more hormones comprise 17-beta estradiol and medroxyprogesterone.

6 . The method of claim 1 , wherein the rate or extent of decidualization is quantified by measuring IGFBP-1 production by the stromal fibroblast cell.

7 . The method of claim 1 , wherein the SFC is identified so as being:
CD45−/CD326−/CD31−/CD90+/CD105+/CD73+.

8 . The method of claim 7 , wherein the SFC is also CD140b+.

9 . The method of claim 1 , wherein the anti-inflammatory agent that targets TNF-alpha or IL-1beta.

10 . A kit for diagnosing a chronic subclinical inflammation of a uterine lining for subsequent treatment, the kit comprising a menstrual cup or polyether polyurethane menstrual sponge, and reagents for maintaining a stromal fibroblast cell (SFC), obtained from a menstrual discharge sample from a subject, under conditions that do not damage decidualization of the SFC.

Assignees

• Feinstein Institutes For Medical Research

Inventors

• Metz Christine
• Gregersen Peter K
• Warren Laura

Classifications

• C12Q1/6844

  Nucleic acid amplification reactions · CPC title

• G01N2800/364

  Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• A61K31/57

  substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone · CPC title